D3 Bio's D3S-001 Receives Two Major FDA Designations for Treating KRAS G12C-Mutated Cancers #Shanghai #United_States #KRAS_G12C #D3S-001 #D3_Bio
0
0
0
0
D3 Bio's D3S-001 Receives Two Major FDA Designations for Treating KRAS G12C-Mutated Cancers #Shanghai #United_States #KRAS_G12C #D3S-001 #D3_Bio
InxMed Reveals Groundbreaking Data on Ifebemtinib and KRAS Inhibitor for Cancer Treatments #China #Nanjing #Cancer_Treatment #KRAS_G12C #Ifebemtinib
FDA Approves Innovative Treatment for KRAS G12C-Colorectal Cancer, Offering Hope for Patients #United_States #Thousand_Oaks #KRAS_G12C #Vectibix #LUMAKRAS